← Human Trials & Peer-Reviewed Studies
N-Terminal Pro-B-Type Natriuretic Peptide as a Marker of Severity of Heart Failure in Children with Congenital Heart Diseases
Plain-language guide to PMID 37563318 (2023): observational study of BNP (Nesiritide) in 32 children.
Key Facts
- PMID
- 37563318
- Journal
- Pediatric cardiology
- Year
- 2023
- Study type
- Observational Study
- Authors
- Chowdhury RR et al. (3 authors)
- DOI
- 10.1007/s00246-023-03259-x
What This Study Did, in Plain Language
What Was Tested
Researchers studied BNP (Nesiritide) in this observational study publication.
So, this study was done to assess the utility of NT-proBNP as a marker of severity of heart failure in children with congenital heart diseases.
Why It Was Studied
N-terminal pro-B-type natriuretic peptide (NT-proBNP) has been used as a tool for diagnosis, severity assessment and prognostication of congestive heart failure (CHF) in adults, with specific cut off values for diagnosis and denoting points of intervention.
However, there is scarcity of paediatric literature regarding role of NT-proBNP as a marker of heart failure severity and prognostication.
Who Took Part
The abstract describes 32 children taking part.
The age groups tagged for this paper are children and adults.
Children (1 month to 5 years), with congenital heart disease, admitted in the paediatric wards with varying severity of CHF were enrolled.
How the Study Was Run
NT-proBNP levels were measured within 24 h of admission.
What Was Measured
N-terminal pro-B-type natriuretic peptide (NT-proBNP) has been used as a tool for diagnosis, severity assessment and prognostication of congestive heart failure (CHF) in adults, with specific cut off values for diagnosis and denoting points of intervention.
Heart failure severity grading was done according to Laer modification of Ross Classification at the time of presentation to hospital and children were classified as having no/grade I CHF (score: 0-2); mild/grade II CHF (score 3-6); moderate/grade III CHF (score 7-9) or severe/grade IV CHF (score 10-12).
The subject headings attached to it are Natriuretic Peptide, Brain, Heart Failure, Heart Defects, Congenital, Peptide Fragments and Biomarkers.
The authors tagged it with the keywords Congenital heart disease, Congestive heart failure, Modified Ross Classification and NT-proBNP.
What This Means in Plain Language
This is an observational study of BNP (Nesiritide) in 32 children.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2023 (Pediatric cardiology), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.